Upfront whole genome and transcriptome sequencing to improve diagnosis in inherited bone marrow failure syndromes

Inherited bone marrow failure syndromes (IBMFS) are monogenic disorders characterized by single or multilineage cytopenias from hypoproliferative dyshematopoiesis. Diagnosis is challenging because of substantial clinical and pathological overlap between individual IBMFS entities and acquired diseases such as immune aplastic anemia. Conventional genetic testing using targeted panels or whole exome sequencing incompletely captures the spectrum of pathogenic variation, leaving a substantial proportion of cases undiagnosed. We evaluated the utility of upfront whole genome and transcriptome sequencing (WGTS) in 237 patients with suspected IBMFS using non-hematopoietic DNA. Median age was 29 years (range 3 months-76 years) and 34.6% were under 18 years. Clinically-accredited sequencing was performed with real-time return of results to guide patient management and familial testing. A molecular diagnosis was established in 87/237 patients (36.7%), spanning hereditary thrombocytopenia, telomere biology disorders, Diamond-Blackfan anemia, severe congenital neutropenia, Shwachman-Diamond syndrome, Fanconi anemia and other IBMFS. A further four patients were diagnosed with non-hematological genetic conditions and seven patients with secondary actionable findings. Novel pathogenic mechanisms including retrotransposon-mediated gene disruption were identified. Further, novel associations with primary IBMFS-like presentations (THRA) as well as definitive evidence of gene-disease associations (MEIS1, TUBB) were established. Acceptability of WGTS based on the established Theoretical Framework of Acceptability was high among patients and carers. Upfront WGTS in suspected IBMFS provides a high diagnostic yield when compared with other genomic approaches, identifies actionable genomic abnormalities, and expands the spectrum of disease mechanisms and gene associations in IBMFS.

Authors

Institutions

Publication Details

Journal
Blood
Published
2026-11-05
DOI
https://doi.org/10.1182/blood.2026035448
Primary Topic
Blood disorders and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Upfront whole genome and transcriptome sequencing to improve diagnosis in inherited bone marrow failure syndromes

Daniel G. MacArthur, Matthew Rhodes Emerson, Mathilda Wilding, Zoe Fehlberg et al.
Blood
Blood disorders and treatments
article

Upfront whole genome and transcriptome sequencing to improve diagnosis in inherited bone marrow failure syndromes

Daniel G. MacArthur, Matthew Rhodes Emerson, Mathilda Wilding, Zoe Fehlberg, Cas Simons, Paul Andrew James, Nicole R. den Elzen, Ing Soo Tiong, Michelle Tan, William S. Stevenson, Graham John Lieschke, Ella R. Thompson, Noel Djitro, Piers A. Blombery, Tracy M. Bryan, Lucy C. Fox, Scott B. Cohen, Francis Baumgartner, Zornitza Stark, Satwica Yerneni, Simon Wu, Anna L Brown, Vahid Pazhakh, David Ritchie, Stephanie Best, Lin Cheng, Kelsey Man, Erin Goode, Laura Barth, Caroline Wong, Erica Wood, Meg Wall
article en

Abstract

Inherited bone marrow failure syndromes (IBMFS) are monogenic disorders characterized by single or multilineage cytopenias from hypoproliferative dyshematopoiesis. Diagnosis is challenging because of substantial clinical and pathological overlap between individual IBMFS entities and acquired diseases such as immune aplastic anemia. Conventional genetic testing using targeted panels or whole exome sequencing incompletely captures the spectrum of pathogenic variation, leaving a substantial proportion of cases undiagnosed. We evaluated the utility of upfront whole genome and transcriptome sequencing (WGTS) in 237 patients with suspected IBMFS using non-hematopoietic DNA. Median age was 29 years (range 3 months-76 years) and 34.6% were under 18 years. Clinically-accredited sequencing was performed with real-time return of results to guide patient management and familial testing. A molecular diagnosis was established in 87/237 patients (36.7%), spanning hereditary thrombocytopenia, telomere biology disorders, Diamond-Blackfan anemia, severe congenital neutropenia, Shwachman-Diamond syndrome, Fanconi anemia and other IBMFS. A further four patients were diagnosed with non-hematological genetic conditions and seven patients with secondary actionable findings. Novel pathogenic mechanisms including retrotransposon-mediated gene disruption were identified. Further, novel associations with primary IBMFS-like presentations (THRA) as well as definitive evidence of gene-disease associations (MEIS1, TUBB) were established. Acceptability of WGTS based on the established Theoretical Framework of Acceptability was high among patients and carers. Upfront WGTS in suspected IBMFS provides a high diagnostic yield when compared with other genomic approaches, identifies actionable genomic abnormalities, and expands the spectrum of disease mechanisms and gene associations in IBMFS.

Blood
South Australia Pathology (AU), Garvan Institute of Medical Research (AU), Children's Medical Research Institute (AU), The University of Melbourne (AU), Royal North Shore Hospital (AU), Peter MacCallum Cancer Centre (AU), Australian Regenerative Medicine Institute (AU), Eastern Health (AU), Monash Health (AU), Murdoch Children's Research Institute (AU), Alfred Health (AU), Monash University (AU), Charité - Universitätsmedizin Berlin (DE)
Openalex Percentile: Top 13%
Blood disorders and treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon